Tremfya rescues J&J’s immunology sales to fuel strong Q3
Johnson & Johnson reported Q3 sales of $25.4bn, beating estimates. Tremfya's sales surged 68.3% to $2.4bn, driving a 7.9% increase in the pharma segment. Overall immunology sales grew 1.3%, offset by declines in Stelara, Remicade, and Simponi. J&J raised its 2026 sales and EPS guidance, despite lower Q3 EPS due to acquisitions and legal settlements. Medtech sales grew 2.5%, led by Shockwave's 16.8% increase.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise are likely to support the stock, while integration costs and settlement charges pose downside risks.
Market read
A large-cap pharma beat with guidance lift can move the broader health‑care sector and major indices.
What to watch
One-time settlement charge and acquisition integration costs could dampen future earnings.
Background
Johnson & Johnson's Q3 results highlight strong performance of Tremfya and medtech growth, offset by declines in legacy immunology drugs.
Ticker impact
Johnson & Johnson posted Q3 sales of $25.4bn beating estimates and raised 2026 guidance to 6.6% sales growth and $11.10 EPS.
likely upward pressure as investors price in the beat and higher guidance
The beat was modest but the guidance lift, especially after a large acquisition, is new and material for a large-cap stock.
Market effects
Immunology and medtech peers may see relative pressure as J&J outperforms.
U.S. large-cap indices could get a modest boost from the beat.
Global pharma stocks may be influenced by J&J's guidance lift.
Counterpoint
The guidance raise is modest and may already be priced in; focus on margin pressure from acquisitions.
Key entities
- CompanyJohnson & Johnson
Global healthcare conglomerate reporting Q3 results.
- ProductTremfya
IL-23 blocker driving immunology sales growth.
